Crossmark

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2023.100291

Published Print: 2023-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Liu, Qi http://orcid.org/0009-0004-0044-9657
Hou, Lingli http://orcid.org/0009-0001-3195-219X
Zhao, Ying http://orcid.org/0009-0000-6071-4572
Yang, Hongwei http://orcid.org/0009-0001-1526-9710
Mo, Zhengying http://orcid.org/0009-0009-7574-0066
Yu, Fei http://orcid.org/0009-0003-2230-7767
License Information

Text and Data Mining valid from 2023-01-01

Text and Data Mining valid from 2023-01-01

Version of Record valid from 2023-10-04
More Information

This article is maintained by: Elsevier

Article Title: Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2023.100291

Content Type: article

Copyright: © 2023 HCFMUSP. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below